Dengpiao Xie1, Naijing Ye2, Mingquan Li2. 1. Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. 2876522253@qq.com. 2. Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Abstract
AIM: To evaluate the efficacy and safety of PA21 versus sevelamer in dialysis patients. METHODS: We searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing PA21 and sevelamer in dialysis patients. RESULTS: Four studies were included. Compared with sevelamer group, PA21 needed fewer mean daily number of tablets (WMD, - 7.97 pill; 95% CI, - 11.28 to - 4.65, p < 0.00001), developed fewer all adverse events (RR = 1.05; 95% CI, 1.00 to 1.11, p = 0.05), and developed fewer gastrointestinal adverse events (RR = 1.32; 95% CI, 1.15 to 1.53, p = 0.0001). There was no significant difference in serum phosphorus between two groups (WMD, - 0.07 mmol/L; 95% CI, - 0.15 to 0.02, p = 0.12). As for serum calcium, there was also no significant difference between two groups (WMD, 0.27 mmol/L; 95% CI, - 0.63 to 1.17, p = 0.55). CONCLUSION: PA21 can effectively control serum phosphorus with lower pill burden and less side effects than sevelamer. PA21 might be another valuable choice for dialysis patients with hyperphosphatemia when patients are unable to tolerate sevelamer.
AIM: To evaluate the efficacy and safety of PA21 versus sevelamer in dialysis patients. METHODS: We searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing PA21 and sevelamer in dialysis patients. RESULTS: Four studies were included. Compared with sevelamer group, PA21 needed fewer mean daily number of tablets (WMD, - 7.97 pill; 95% CI, - 11.28 to - 4.65, p < 0.00001), developed fewer all adverse events (RR = 1.05; 95% CI, 1.00 to 1.11, p = 0.05), and developed fewer gastrointestinal adverse events (RR = 1.32; 95% CI, 1.15 to 1.53, p = 0.0001). There was no significant difference in serum phosphorus between two groups (WMD, - 0.07 mmol/L; 95% CI, - 0.15 to 0.02, p = 0.12). As for serum calcium, there was also no significant difference between two groups (WMD, 0.27 mmol/L; 95% CI, - 0.63 to 1.17, p = 0.55). CONCLUSION: PA21 can effectively control serum phosphorus with lower pill burden and less side effects than sevelamer. PA21 might be another valuable choice for dialysis patients with hyperphosphatemia when patients are unable to tolerate sevelamer.
Authors: Rachel B Fissell; Angelo Karaboyas; Brian A Bieber; Ananda Sen; Yun Li; Antonio A Lopes; Takashi Akiba; Jürgen Bommer; Jean Ethier; Michel Jadoul; Ronald L Pisoni; Bruce M Robinson; Francesca Tentori Journal: Hemodial Int Date: 2015-05-14 Impact factor: 1.812
Authors: Wajeh Qunibi; Moustafa Moustafa; Larry R Muenz; David Y He; Paul D Kessler; Jose A Diaz-Buxo; Mathew Budoff Journal: Am J Kidney Dis Date: 2008-04-18 Impact factor: 8.860
Authors: Benjamin J Swanson; Berkeley N Limketkai; Ta-Chiang Liu; Elizabeth Montgomery; Kamran Nazari; Jason Y Park; William C Santangelo; Michael S Torbenson; Lysandra Voltaggio; Martha M Yearsley; Christina A Arnold Journal: Am J Surg Pathol Date: 2013-11 Impact factor: 6.394
Authors: Jürgen Floege; Adrian C Covic; Markus Ketteler; Johannes F E Mann; Anjay Rastogi; Bruce Spinowitz; Edward M F Chong; Sylvain Gaillard; Laura J Lisk; Stuart M Sprague Journal: Nephrol Dial Transplant Date: 2015-02-16 Impact factor: 5.992
Authors: Jürgen Floege; Adrian C Covic; Markus Ketteler; Anjay Rastogi; Edward M F Chong; Sylvain Gaillard; Laura J Lisk; Stuart M Sprague Journal: Kidney Int Date: 2014-03-19 Impact factor: 10.612
Authors: Kamyar Kalantar-Zadeh; Linda H Ficociello; Vidhya Parameswaran; Nicolaos V Athienites; Claudy Mullon; Robert J Kossmann; Daniel W Coyne Journal: BMC Nephrol Date: 2019-10-29 Impact factor: 2.388